ARGX ArGEN-X SE

argenx to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference

argenx to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference



August 4, 2020



Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 11, 2020 at 12:35 p.m. ET.

A live webcast of the presentation will be available on the Company’s website at . A replay of the webcast will be available for 90 days following the presentation.

About argenx

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx is translating immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx is evaluating efgartigimod in multiple serious autoimmune diseases, and cusatuzumab in hematological cancers in collaboration with Janssen. argenx is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx has offices in Belgium, the United States and Japan. For more information, visit and follow us on LinkedIn at .



For further information, please contact:

Beth DelGiacco, Vice President, Investor Relations (US)





Joke Comijn, Director Corporate Communications & Investor Relations (EU)

+32 (0)477 77 29 44

+32 (0)9 310 34 19

EN
04/08/2020

Underlying

ARGXArGEN-X SE

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ArGEN-X SE

Guy Sips ... (+5)
  • Guy Sips
  • Kristof Samoy
  • Michiel Declercq
  • Thomas Vranken
  • Wim Lewi
EURN EURONAV NV
EVS EVS BROADCAST EQUIPMENT SA
VGP VGP NV
ARGX ARGEN-X SE
TKWY JUST EAT TAKEAWAY.COM N.V.
FAST FASTNED
DEME DEME GROUP NV
04/16/24 April 16, 2024 1 EN
Thomas Vranken
  • Thomas Vranken
ARGX ARGEN-X SE

argenx FIRST LOOK: Additional CIDP data at AAN

argenx announced additional detail on its Phase 3 ADHERE data with Vyvgart Hytrulo, showcasing its speed of onset and depth of response. We believe that Vyvgart Hytrulo is well positioned vs. the approved standard-of-care IVIg/SCIg across patient types, and look forward to the FDA decision (PDUFA: June 21, 2024). € 435 TP and Buy rating reiterated.

04/16/24 April 16, 2024 1 EN
 PRESS RELEASE
Free
ARGX ARGEN-X SE

argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive ...

argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease ADHERE data show VYVGART® Hytrulo has potential to be first advancement for CIDP patients in 30 years Real-world data demonstrate gMG patients able to significantly reduce steroid use over first six months of initiating VYVGART® treatment April 16, 2024 – 7:00am CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, ...

April 16, 2024 1 EN
David Seynnaeve ... (+2)
  • David Seynnaeve
  • PhD
ARGX ARGEN-X SE

argenx - New CIDP & gMG data further underlines VYVGART (Hytrulo)'s va...

• ARGX shared additional results from the ADHERE (open-label) study and real-world data from gMG patients at the AAN Annual Meeting. • Data indicates rapid, deep, and clinically meaningful/sustained improvements in CIDP & with ability to reduce steroid burden (gMG). • We expect a positive outcome of the decision on regulatory approval for CDP by June 21 (85% LoA, +4% impact on TP) and currently project low double-digit million in sales this year. This might seem rather conservative (vs. gMG init...

04/16/24 April 16, 2024 1 EN
Damien Choplain ... (+2)
  • Damien Choplain
  • Martial Descoutures
HEIA HEINEKEN NV
BRBY BURBERRY GROUP PLC
RAA RATIONAL AG
MERLIN MERLIN PROPERTIES SOCIMI S.A.
AT1 AROUNDTOWN SA
ARGX ARGEN-X SE
ATCO A ATLAS COPCO AB
03/27/24 March 27, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch